Irritable Bowel Syndrome Drugs Market - Top Companies and Manufacturers

  • Report ID: 3040
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Companies Dominating the Irritable Bowel Syndrome Drugs Landscape

    • Abbott Services
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Ardelyx, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca
    • GlaxoSmithKline Plc
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Ironwood Pharmaceuticals, Inc.
    • Synergy Pharma Consultancy Private Limited
    • Synthetic Biologics, Inc 

Browse Key Market Insights with Data Illustration:

In the News

  • IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.

  •  Indegene a provider of technology-driven healthcare solutions, and metaMe Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).


Author Credits:  Radhika Pawar


  • Report ID: 3040
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of irritable bowel syndrome drugs is estimated at USD 4.43 billion.

The irritable bowel syndrome drugs market size was over USD 4.14 billion in 2024 and is projected to cross USD 11.53 billion by the end of 2037, growing at more than 8.7% CAGR during the forecast period i.e., between 2025-2037. Increasing incidences of irritable bowel syndrome and growing availability of over the counter drugs will impel the market growth.

North American region is anticipated to hold the largest share by 2037, driven by increasing frequency of fecal incontinence and the availability of efficient treatment options in the region.

The major players in the market include Abbott Services, Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Ironwood Pharmaceuticals, Inc., Synergy Pharma Consultancy Private Limited, Synthetic Biologics, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample